Evidence map›Paper›PMID 25697665›Full record

ArticleMicrobial pathogenesis2015

Further characterization of a highly attenuated Yersinia pestis CO92 mutant deleted for the genes encoding Braun lipoprotein and plasminogen activator protease in murine alveolar and primary human macrophages.

Christina J van Lier, Bethany L Tiner, Sadhana Chauhan, Vladimir L Motin, Eric C Fitts, Matthew B Huante, Janice J Endsley, Duraisamy Ponnusamy, Jian Sha, Ashok K Chopra

Open access · greenAbstract read
In one paragraph

Article in Microbial pathogenesis, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Plague vaccines: new developments in an ongoing search.Applied microbiology and biotechnology · 2021
    Review
  5. Biomolecules · 2020
    Review
  6. Article
  7. Impact of Gentamicin Concentration and Exposure Time on IntracellularFrontiers in cellular and infection microbiology · 2017
    Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Christina J van LierDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Bethany L TinerDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Sadhana ChauhanDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Vladimir L MotinDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA; Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, TX 77555, USA; Center for Biodefense and Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, TX 77555, USA; Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX 77555, USA; Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Eric C FittsDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Matthew B HuanteDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Janice J EndsleyDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA; Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, TX 77555, USA; Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX 77555, USA.
Duraisamy PonnusamyDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Jian ShaDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA; Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX 77555, USA. Electronic address: jisha@utmb.edu.
Ashok K ChopraDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA; Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, TX 77555, USA; Center for Biodefense and Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, TX 77555, USA; Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX 77555, USA. Electronic address: achopra@utmb.edu.
The University of Texas Medical Branch at Galveston · US

Funding

Health, Safety and Training ServicesUC7AI070083 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI LEMON, STANLEY M. · 2006 to 2010
$49.5M
Identification of New Antigens for a Plague VaccineR01AI064389 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI CHOPRA, ASHOK K · 2005 to 2015
$3.8M
Biodefense Training ProgramT32AI060549 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI ASHOK K CHOPRA, Janice J Endsley · 2004 to 2026
$3.0M
NIAID NIH HHS AI060549NIAID NIH HHS AI064389NIAID NIH HHS AI070083NIAID NIH HHS R01 AI064389NIAID NIH HHS T32 AI060549NIAID NIH HHS UC7 AI070083
6 · The paper itself

Abstract

We recently characterized the Δlpp Δpla double in-frame deletion mutant of Yersinia pestis CO92 molecularly, biologically, and immunologically. While Braun lipoprotein (Lpp) activates toll-like receptor-2 to initiate an inflammatory cascade, plasminogen activator (Pla) protease facilitates bacterial dissemination in the host. The Δlpp Δpla double mutant was highly attenuated in evoking bubonic and pneumonic plague, was rapidly cleared from mouse organs, and generated humoral and cell-mediated immune responses to provide subsequent protection to mice against a lethal challenge dose of wild-type (WT) CO92. Here, we further characterized the Δlpp Δpla double mutant in two murine macrophage cell lines as well as in primary human monocyte-derived macrophages to gauge its potential as a live-attenuated vaccine candidate. We first demonstrated that the Δpla single and the Δlpp Δpla double mutant were unable to survive efficiently in murine and human macrophages, unlike WT CO92. We observed that the levels of Pla and its associated protease activity were not affected in the Δlpp single mutant, and, likewise, deletion of the pla gene from WT CO92 did not alter Lpp levels. Further, our study revealed that both Lpp and Pla contributed to the intracellular survival of WT CO92 via different mechanisms. Importantly, the ability of the Δlpp Δpla double mutant to be phagocytized by macrophages, to stimulate production of tumor necrosis factor-α and interleukin-6, and to activate the nitric oxide killing pathways of the host cells remained unaltered when compared to the WT CO92-infected macrophages. Finally, macrophages infected with either the WT CO92 or the Δlpp Δpla double mutant were equally efficient in their uptake of zymosan particles as determined by flow cytometric analysis. Overall, our data indicated that although the Δlpp Δpla double mutant of Y. pestis CO92 was highly attenuated, it retained the ability to elicit innate and subsequent acquired immune responses in the host similar to that of WT CO92, which are highly desirable in a live-attenuated vaccine candidate.

Indexed as

Gene DeletionAnimalsCells, CulturedHumansImmunity, InnateLipoproteinsMacrophagesMacrophages, AlveolarMiceMicrobial ViabilityPeptide HydrolasesPlague VaccinePlasminogen ActivatorsVaccines, AttenuatedVirulenceYersinia pestisLipoproteinsPeptide HydrolasesPlague VaccinePlasminogen ActivatorsVaccines, AttenuatedAlveolar macrophagesBraun lipoproteinHuman monocyte-derived macrophagesInnate immunityIntracellular survivalPlasminogen activator proteaseYersinia pestis

Identifiers

PMID25697665
PMCPMC4363157
OpenAlexW2123152912

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.